Neratinib: Inching Up on the Cure Rate of HER2+ Breast Cancer?
Related Experiment Video
Updated: Feb 10, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
Nisha Unni1, Dhivya R Sudhan2, Carlos L Arteaga3,4
1Department of Medicine, UT Southwestern Medical Center, Dallas, Texas.
Abstract:
Neratinib was recently approved by the FDA for extended adjuvant treatment of HER2+ breast cancer. The ExteNET trial showed improvement in invasive disease-free survival (iDFS) in the neratinib arm compared with placebo. The benefit was more pronounced in patients with estrogen receptor-positive (ER+)/HER2+ tumors, suggesting bidirectional cross-talk between the ER and HER pathways. Clin Cancer Res; 24(15); 3483-5. ©2018 AACRSee related article by Singh et al., p. 3486.
Related Concept Videos
Curing of Concrete
Curing Methods
Accelerated Curing of Concrete
Reaction Rate
The mathematical representation of the change in the concentration of reactants and products, over time, is the rate...
Related Rates
Speciation Rates

